Next Article in Journal
A Validated Chiral LC–MS/MS Method for the Enantioselective Determination of (S)-(+)- and (R)-(-)-Ibuprofen in Dog Plasma: Its Application to a Pharmacokinetic Study
Next Article in Special Issue
High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma
Previous Article in Journal
Polydopamine-Coated Cu-BTC Nanowires for Effective Magnetic Resonance Imaging and Photothermal Therapy
Previous Article in Special Issue
Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 3
10.3390/pharmaceutics15030823
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?

by
Sofia España Fernandez
1,2,*,
Chen Sun
3,
Carme Solé-Blanch
2,
Aram Boada
4,
Anna Martínez-Cardús
2 and
José Luis Manzano
1,2
1
Medical Oncology Department, Catalan Institute of Oncology Badalona, 08916 Badalona, Spain
2
Badalona-Applied Research Group in Oncology (B-ARGO), IGTP (Health Research Institute Germans Trias i Pujol), 08916 Badalona, Spain
3
Department of Tumor Radiotherapy, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
4
Dermatology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(3), 823; https://doi.org/10.3390/pharmaceutics15030823
Submission received: 24 December 2022 / Revised: 25 February 2023 / Accepted: 27 February 2023 / Published: 2 March 2023
(This article belongs to the Special Issue Drug Repurposing and Delivery Systems for Immunotherapy)
Browse Figure
Versions Notes

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum previously unknown to clinicians, until now. A common situation in daily practice is that a patient experiences toxicity due to this type of drug and we need to resume or rechallenge treatment after resolving the adverse event. Methods: A PubMed literature review was carried out. Results: The published data regarding the resumption or rechallenge of ICI treatment in melanoma patients is scarce and heterogeneous. Depending on the study reviewed, the recurrence incidence of grade 3–4 immune-related adverse events (irAEs) ranged from 18% to 82%. Conclusion: It is possible to resume or rechallenge, but each patient should be evaluated by a multidisciplinary team for close monitoring and assessment of the risk/benefit ratio before initiating treatment.
Keywords: immunotherapy; immune checkpoints; rechallenge; resumption; toxicity immunotherapy; immune checkpoints; rechallenge; resumption; toxicity

Share and Cite

MDPI and ACS Style

España Fernandez, S.; Sun, C.; Solé-Blanch, C.; Boada, A.; Martínez-Cardús, A.; Manzano, J.L. Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance? Pharmaceutics 2023, 15, 823. https://doi.org/10.3390/pharmaceutics15030823

AMA Style

España Fernandez S, Sun C, Solé-Blanch C, Boada A, Martínez-Cardús A, Manzano JL. Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance? Pharmaceutics. 2023; 15(3):823. https://doi.org/10.3390/pharmaceutics15030823

Chicago/Turabian Style

España Fernandez, Sofia, Chen Sun, Carme Solé-Blanch, Aram Boada, Anna Martínez-Cardús, and José Luis Manzano. 2023. "Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?" Pharmaceutics 15, no. 3: 823. https://doi.org/10.3390/pharmaceutics15030823

APA Style

España Fernandez, S., Sun, C., Solé-Blanch, C., Boada, A., Martínez-Cardús, A., & Manzano, J. L. (2023). Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance? Pharmaceutics, 15(3), 823. https://doi.org/10.3390/pharmaceutics15030823

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop